Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) EBIT: 2017-2024

Historic EBIT for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to -$330.0 million.

  • Arcus Biosciences' EBIT fell 35.24% to -$142.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$375.0 million, marking a year-over-year decrease of 17.92%. This contributed to the annual value of -$330.0 million for FY2024, which is 2.94% up from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' EBIT is -$330.0 million, which was up 2.94% from -$340.0 million recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' EBIT ranged from a high of $54.0 million in FY2021 and a low of -$340.0 million during FY2023.
  • Over the past 3 years, Arcus Biosciences' median EBIT value was -$330.0 million (recorded in 2024), while the average stood at -$316.7 million.
  • In the last 5 years, Arcus Biosciences' EBIT surged by 143.55% in 2021 and then crashed by 618.52% in 2022.
  • Over the past 5 years, Arcus Biosciences' EBIT (Yearly) stood at -$124.0 million in 2020, then spiked by 143.55% to $54.0 million in 2021, then crashed by 618.52% to -$280.0 million in 2022, then declined by 21.43% to -$340.0 million in 2023, then rose by 2.94% to -$330.0 million in 2024.